MHRA considers Lamisil Once switch
This article was originally published in The Tan Sheet
Executive Summary
Novartis asks the U.K. Medicines and Healthcare products Regulatory Agency to switch Lamisil Once 1% Cutaneous Solution (terbinafine hydrochloride 1 percent) from pharmacy to general sales. MHRA seeks comment on the switch of the athlete's foot treatment for adults 18 years and older, according to a June 8 release. Comments are due July 6. Novartis notes in the application that the product poses only a small health hazard and misuse is low while the incidence of athlete's foot is high
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.